title: Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients.
abstract: OBJECTIVE
  To compare the clinical efficacy of intravitreal injections of bevacizumab and ranibizumab for treating Chinese patients with neovascular age-related macular degeneration (AMD).
  
  
  METHODS
  Among 60 Chinese patients with exudative AMD (60 eyes), 28 received intravitreal bevacizumab injections (1.25mg) and 32 received intravitreal ranibizumab injections (0.5mg), once a month for 3 months and were followed for a total of 6 months. Monthly optical coherence tomography (OCT) was used to determine whether the patients received additional treatments during the follow-up. We compared the baseline and 6-month follow-up values of mean best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in both groups of patients. We also compared the occurrence of adverse events.
  
  
  RESULTS
  At the 6-month follow-up, the mean BCVA (logMAR) of the bevacizumab and ranibizumab treatment groups improved from the baseline measurements of 0.72±0.23 and 0.73±0.22 to 0.47±0.14 and 0.45±0.20, respectively (P<0.05 for both groups). However, the change was not significantly different between the two groups. As evaluated by OCT, CRT decreased from 366.71±34.72µm and 352±36.9µm at baseline to 250.86±41.51µm and 243.22±41.38µm in the bevacizumab and ranibizumab groups, respectively (P<0.05 for both groups). However, the change was not significantly different between the two groups. There were no severe local adverse reactions or systemic adverse events.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab and ranibizumab have equivalent effects on BCVA and CRT and appeare safe over the short-term.
authors: Department of Ophthalmology, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
authors: Jun
authors: J
authors: Li
authors: Han
authors: H
authors: Zhang
authors: Peng
authors: P
authors: Sun
authors: Feng
authors: F
authors: Gu
authors: Zhe-Li
authors: ZL
authors: Liu
keywords: age-related macular degeneration; bevacizumab (avastin); choroidal neovascularization; ranibizumab (lucentis)
references: Clin Exp Ophthalmol. 2010 Jan;38(1):84
references: 20447111
references: Graefes Arch Clin Exp Ophthalmol. 2009 Jan;247(1):1-11
references: 18843500
references: Am J Ophthalmol. 2006 Jul;142(1):95-104
references: 16815256
references: Ophthalmology. 2009 Oct;116(10 Suppl):S15-23
references: 19800535
references: J Cataract Refract Surg. 2004 Feb;30(2):287-90
references: 15030802
references: Br J Ophthalmol. 2007 Sep;91(9):1244-6
references: 17431015
references: Graefes Arch Clin Exp Ophthalmol. 2007 Nov;245(11):1597-602
references: 17437123
references: Am J Ophthalmol. 2012 Feb;153(2):300-306.e1
references: 21982109
references: Angiogenesis. 1999;3(1):33-9
references: 14517442
references: Zhonghua Yan Ke Za Zhi. 2005 Jan;41(1):15-9
references: 15774107
references: Clin Exp Optom. 2012 Sep;95(5):541-3
references: 22672003
references: Am J Ophthalmol. 2005 Apr;139(4):589-96
references: 15808152
references: Ophthalmology. 2012 Jul;119(7):1399-411
references: 22578446
references: Am J Ophthalmol. 2007 Dec;144(6):850-857
references: 17949673
references: Cancer Metastasis Rev. 1993 Sep;12(3-4):303-24
references: 8281615
references: Br J Ophthalmol. 2013 Mar;97(3):266-71
references: 23292928